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Treatment of experimental animals with prototypical
enzyme inducers represents a useful tool to character-
ize the role of different isozymes in drug metabolism
and to improve our knowledge on factors regulating
their synthesis at the transcriptional level. The effect
of model enzyme inducers on phase II (conjugating)
enzyme families, including UDP-glucuronosyltrans-
ferase’s and glutathione-S-transferase’s, has been well
characterized in rodent liver. More recently, the effect
of inducers on the expression of canalicular multidrug
resistance-associated protein 2 (Mrp2) has been fo-
cused upon. The identification of a number of conju-
gated drugs as Mrp2 substrates suggests that both the
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Co-regulation of expression of phase II
metabolizing enzymes and multidrug
resistance-associated protein 2
Viviana A. Catania, PhD;1 Enrique J. Sánchez Pozzi, PhD; 1 Marcelo G. Luquita, PhD;1 María L. Ruiz, PhD;1 Silvina S.M.
Villanueva, PhD;1 Brett Jones, PhD;2 Aldo D. Mottino, PhD1,2
conjugation and transport systems act coordinately to
improve drug elimination from the body. We provide
evidence about circumstances resulting in the simulta-
neous upregulation of phase II enzymes and Mrp2 in
hepatic and extrahepatic tissues, most likely involving
activation of common nuclear receptors (e.g. FXR,
PXR). Additionally, we provide an analysis of exam-
ples of drug-induced toxicity leading to the simulta-
neous downregulation of both systems. Potential ther-
apeutic strategies based on the modulation of expres-
sion of these systems are also briefly commented upon.
Key words: UDP-glucuronosyltransferase, glutathione-
S-transferase, protein induction, cholestasis, nuclear re-
ceptors.
Introduction
The phase II or post-oxidative biotransformation system
comprises an array of enzymes that catalyze the incorpora-
tion of a new hydrophilic endogenous group into hydro-
phobic molecules, thereby decreasing its polarity and even-
tual toxicity. Phase II reactions can be catalyzed by a num-
ber of different enzyme families including
UDP-glucuronosyltransferase (UGT), glutathione S-trans-
ferase (GST), sulphotransferase and methytransferase. The
multidrug resistant proteins (MRPs) represent a family of
ATP-dependent transporters that are expressed normally in
epithelial cells, but which exhibit elevated expression lev-
els in tumoral cells. Mrp2, one member of the MRP family,
is preferentially localized in the apical membrane of hepa-
tocytes,1 renal tubular cells2 and enterocytes.3 Mrp2 is in-
volved in the secretion of a large number of conjugated
compounds, with most Mrp2 substrates being conjugated
derivatives of endogenous compounds, drugs and carcino-
gens (Figure 1).1 Consequently, they may act coordinately
to eliminate these compounds from the body.
Hepatic and extrahepatic metabolism
of xenobiotics in the normal state
On any given day, an average person may be exposed
to literally thousands of different molecules. Some of
© 2019, Fundación Clínica Médica Sur, A.C. Published by Elsevier España S.L.U. This is an open access article under the CC BY-NC-ND 
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these substances, such as carbohydrates and proteins, are
necessary sources of nutrition and are processed in re-
fined biochemical systems. However, humans and other
biological organisms are also exposed throughout their
lifetime to a vast array of xenobiotics including pharma-
cological drugs, environmental pollutants and natural tox-
ins. The major routes of exposure to foreign chemicals in-
clude ingestion in the diet, inhalation or absorption (e.g.
skin, GI). More specifically, oral exposure can occur via
the ingestion of food and drugs or by swallowing part of
the inhaled xenobiotics after clearance from the tracheo-
bronchial tree.4 Most xenobiotics to some degree undergo
a first-pass metabolism in which their biotransformation
within enterocytes and hepatocytes prevents their distri-
bution throughout the body, and thereby facilitates their
clearance. Hepatic first-pass clearance has been exten-
sively studied,5 in addition, the role of the small intestine
as an intrinsic component of presystemic elimination of
xenobiotics has also been elucidated.6 Chemicals ab-
sorbed into the portal system are transported to the liver,
the major site of biotransformation in the body. Nife-
dipine for example, a well-absorbed drug, is subjected to
first-pass phase I metabolism in humans resulting in an
oral bioavailability of less than 50%.7 Similarly, phase II
reactions in liver and intestine (mediated by UGT and
GST isoenzymes) also play a significant role in first-pass
clearance of drugs and dietary xenobiotics.8-11 For exam-
ple, following oral administration, morphine undergoes
significant first-pass metabolism through conjugation
with glucuronic acid thus leading to the 3- and 6-deriva-
tives, in addition to oxidative metabolism.12 Hepatic and
intestinal production of morphine-6-glucuronide is partic-
ularly relevant because of the high rate of synthesis and
activity that is known to be greater than the parent com-
pound.13 Numerous other drugs including ethynylestradi-
ol (EE), salicilic acid, paracetamol, chloramphenicol,
propanolol and oxacepan, also undergo first-pass conju-
gation reactions, and are predominantly catalyzed by
members of the UGT enzyme family in both liver and in-
testine.14-16 Following phase II metabolism, the conjugat-
ed derivatives are secreted through the apical membrane
in a process mediated by Mrp2.
Normal localization and function of
Phase II enzymes and Mrp2
Liver cells express both phase II enzymes and Mrp2,
thereby accounting for the metabolism and excretion of a
wide variety of endogenous and exogenous compounds
in the hepatocyte. In many instances, conjugation is a pre-
requisite for the compound to be recognized by the trans-
porter. For example, bilirubin requires conjugation with
glucuronic acid before it can be secreted into bile.17 The
biotransformation of compounds within the liver general-
ly culminates in a variety of oxidative (e.g. hydroxylat-
ed), conjugated or mixed substrates. Recently, Dietrich et
al reported that Mrp2 is involved in the secretion into bile
of several different metabolites of 2-amino-1-methyl-6-
phenyl-imidazo[4,5-b]pyridine (PhIP), the most abundant
carcinogen in overcooked meat.18 The authors compared
the biliary excretion of intact and hydroxylated PhIP glu-
curonides, the main derivatives of PhIP, between normal
and Mrp2 genetically-deficient (TR-) rats, and observed
that their secretion was decreased in TR- animals by al-
most 50%. The substrates exhibiting the highest Vmax/
Km values for Mrp2, among a range of compounds test-
ed, were the glutathione derivatives of leukotriene C4
(LTC4), dinitrophenyl-glutathione (GS-DNP), estradiol
17β-glucuronide and bilirubin mono- and di-glucu-
ronides.1 Therefore, conjugated derivatives are not the
unique, but probably the preferential substrates for Mrp2.
Immunohistochemical analyses in the normal rat liver
have demonstrated that UGTs are localized in both peri-
portal and perivenous hepatocytes, and that Mrp2 is also
expressed in both regions.19,20 Studies on the localization
of UGTs and MRPs in the kidney have also suggested
that they may work in cooperation. Several different UGT
and Mrp2 isoforms have also been localized to tubular
cells from the renal cortex in rats.20,21 A similar distribu-
tion profile was observed in the human kidney.22,23 In the
rat intestine, glucuronic acid, glutathione and sulfate con-
jugation of endogenous and exogenous substrates repre-
sents the highest activities in the proximal portion with a
decrease observed further down the intestinal tract.24-26
Furthermore, a gradient in UGT and GST enzyme activi-
ty has been demonstrated along the villus-crypt axis with
the highest activities at the tip of the villus and the lowest
at the crypt region.20,27 A similar distribution along the
small intestine and villus-crypt axis has been reported for
intestinal Mrp2.3
The evidence clearly indicates the overlapping local-
ization and coordinated function between phase II en-
zymes and the apical export pump Mrp2, and thereby fa-
cilitating the elimination of potentially harmful endoge-
nous substrates and xenobiotics from the body.
Expression and activity of phase II enzymes
and Mrp2 in response to inducers.
Role of nuclear receptors
The expression and activity of enzymatic systems and
transporters can be affected by many factors, including
enzyme inducers, aging, diet, disease and hormones.10,15,28-
30 Regulation may occur either at the transcriptional level,
resulting in changes in mRNA and protein contents, or at
the level of post-translational processing. In general, the
major mechanism by which inducers increase the rate of
biotransformation is by activation through a number of
ligand-activated transcription factors. Examples of
ligand-activated transcription factors include the aryl hy-
drocarbon receptor (AhR), constitutive androstane recep-
tor (CAR), pregnane X receptor (PXR), peroxisome pro-












liferator-activated receptor (PPAR), 9-cis-retinoic acid
receptor (RXR/RAR) and antioxidant/electrophile re-
sponse element (ARE/EpRE), among others.31-33
It has been well documented that the activity of the
conjugating enzymes, UGT and GST, are significantly in-
creased in liver and small intestine following treatment
with various chemicals. Generally, these inductions are
due to an increased expression of specific isoforms. Phe-
nobarbital (PB) and spironolactone (SL), two prescription
drugs, have demonstrated inducing properties on Phase I
and II systems as well as on genes encoding transporter
proteins. Importantly, the nuclear receptor, CAR, has re-
cently been implicated in mediating responses associated
with PB exposure.34 In addition, PXR is activated by a va-
riety of natural steroids and xenobiotics, including preg-
nenolone-16α-carbonitrile, dexamethasone and SL.35
It has previously been reported that following treat-
ment of animals with PB the protein content, activity and
mRNA levels of hepatic and intestinal GST isoforms be-
longing to the alpha and mu classes were significantly in-
creased.33,36,37 PB administration was also able to increase
the hepatic glucuronidation rate towards different sub-
strates,38,39 as well as protein content and mRNA levels of
specific UGT isoenzymes.40-43
The reported literature on the effect of PB on hepatic
Mrp2 expression is contradictory and is dependent upon
the experimental model used and the time course studied.
For example, Klaassen and Johnson reported that preg-
nenolone-16α-carbonitrile and PB induced Mrp2 expres-
sion in liver, as well as the subsequent biliary excretion of
Mrp2 substrates.44 Both compounds were also reported to
induce phase II enzyme expression including specific
UGT isoforms.45 Furthermore, Kast et al. described that
Mrp2 mRNA levels were significantly increased by PB in
vitro46 while Patel et al.47 showed that Mrp2 protein ex-
pression and functional capacity was decreased 48 h after
PB treatment. Finally, Hagenbuch et al.48 reported a mod-
est increase in Mrp2 expression at the RNA level after PB
treatment without washout.
Several studies have demonstrated that activation of
PXR enhances the expression of hepatic GST and UGT
isoenzymes.33,49,50 Studies from our laboratory have
showed that GST activity towards 1-chloro-2,4-dini-
trobenzene (CDNB), as well as the glucuronidation rates
of bilirubin and ethynylestradiol in rat, are increased by
SL.51-54 More specifically, western blot analyses revealed
increased UGT1A1 (bilirubin), UGT1A5 (3-OH ethy-
nylestradiol), and 2B1 (17β-OH ethynylestradiol) protein
levels. Furthermore, a northern blot analysis revealed that
the up-regulation observed was at the transcriptional lev-
el. A report55 recently showed that activation of PXR and
CAR induced hepatic UGT1A1 and UGT1A6 expression,
and subsequently increased bilirubin clearance.
To assess whether Mrp2 followed a similar induction
profile to phase II enzymes in SL-treated rats, we exam-
ined its expression and activity in liver and intestine.
Through western blot analyses we observed that both he-
patic and intestinal Mrp2 protein increased significantly
in SL-treated rats with respect to controls. An in situ im-
munofluorescence analysis of Mrp2 expression con-
firmed the immunoblotting data. Furthermore, an analysis
of transport activity in liver revealed that biliary secretion
of glutathione, a substrate for Mrp2, was also increased
by SL, in agreement with the increased expression of the
transporter,56 [unpublished results]. Additional authors
have also reported the induction of Mrp2 expression by
PXR ligands.35,46,55
Thus, the common localization of phase II enzymes
with their transport systems in conjunction with their in-
duction by the same compounds, suggests a coordinate
action. A study by Bock et al has provided additional evi-
dence in support of the hypothesis of co-regulation. They
reported that treatment of Caco-2 cells with the polyphe-
nolic antioxidants quercetin and t-butylhydroquinone in-
creased Mrp2 expression.58 Selected UGT isoforms in-
volved in the conjugation of phenolic compounds (i.e.,
UGT1A6) were also induced, leading the authors to pos-
tulate that coordinate induction of UGT and Mrp2 may
facilitate chemoprotection against phenolic toxins and ex-
cretion of conjugates in the intestinal lumen. Finally,
Huang et al.59 showed that activation of CAR increases
hepatic expression of genes known to be involved in bi-
lirubin metabolism and transport across the apical liver
membrane (i.e. GSTA1, UGT1A1 and Mrp2).
Figure 1. Phase II metabolism and transport of endo and xenobiotics
in the liver and their regulation by nuclear receptors. Hydrophobic xe-
nobiotics may enter the cell by diffusion through the basolateral mem-
brane in the hepatocyte. After conjugation in the endoplasmic reticu-
lum by UDP-glucuronosyltransferase (UGT) or in the cytosol by Glu-
tathione-S-Transferase (GST) or sulfotransferase, the product may be
secreted into bile by Mrp2. The nuclear Pregnane X Receptor (PXR) is
activated by a large number of endogenous and exogenous chemicals
including steroids, antibiotics, antimycotics, bile salts, etc, thus ser-
ving as a generalized sensor of hydrophobic toxins. Generally, the
transcriptional activation via CAR and PXR involves the formation of
heterodimers between these receptors and 9-cis-retinoic acid receptor
(RXR). Then, the heterodimer bind to response elements in the regula-
tory regions of target genes.
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Co-regulation of Mrp2 and phase II
metabolism in cholestasis
Cholestasis is a pathological condition where a co-reg-
ulation of Mrp2 and Phase II detoxification is observed.
Trauner et al. demonstrated that in both extrahepatic and
intrahepatic models of cholestasis, Mrp2 is down regulat-
ed.60 Bile duct ligation produced a significant decrease in
Mrp2 protein as determined by western blotting 3 days
after surgery (47%) and is still present after 7 days (73%).
This was correlated with an observed decrease in Mrp2
steady-state mRNA levels. Lipopolysaccharide (LPS)-
treated rats, a model of intrahepatic cholestasis in sepsis,
exhibited similar results. Specifically, 16 hs. after a sin-
gle-dose administration of the endotoxin (4 mg/kg bw),
Mrp2 protein is reduced by 70% and observed mRNA
levels are only 10% of control values. At this time, Mrp2
function is maximally decreased.61-63 The administration
of ethynylestradiol to experimental animals represents an
additional model of intrahepatic cholestasis. After a 5-day
administration of 5 mg/kg bw, Mrp2 function is clearly
altered.64-67 More specifically, Mrp2 protein is reduced by
57% but steady-state mRNA levels are not modified by
the estrogen.60 It is therefore apparent that different mech-
anisms are involved in Mrp2 regulation in cholestasis. In
summary, LPS and bile duct ligation seem to regulate
Mrp2 at the mRNA level, whereas the effect of ethy-
nylestradiol is limited to posttranscriptional events.
Decreased Mrp2 expression and function during
cholestasis may have important implications for the ex-
cretion of various, potentially toxic endo- and xenobiot-
ics.1,68 The compounds generally undergo phase II metab-
olism via GST or UGT enzymes, with the related meta-
bolic processes also being affected in the different models
of cholestasis. Bile duct ligation leads to a 33% decrease
in the glucuronidation of bilirubin within 48 hs, reaching
70% 8 days after surgery.69 Furthermore, GST enzyme
activity measured using CDNB is decreased by 40% 14
days post ligation.70 Endotoxin administration also affects
GST and UGT activity.71,72 The mRNAs of GSTA2, A3,
M1 and M2 decrease reaching a minimum between 6 to
12 hs. after the administration of LPS (1 mg/kg bw).71
In ethynylestradiol-treated rats, UGT and GST enzyme
activities are markedly reduced.61,73 Glucuronidation of
ethynylestradiol is significantly decreased, correlating
with a decrease in UGT2B1 protein as measured by west-
ern blotting.73 Since ethynylestradiol 17β-glucuronide is
the postulated mediator of cholestasis,74 this decrease can
have a protective aim.
A common mechanism for the down-regulation of
phase II enzymes and Mrp2 is suggested by the evidence.
In the endotoxin model, and probably in bile-duct ligated
rats, inflammatory cytokines may be involved.75 IL-1β
participates in Mrp2 mRNA reduction induced by LPS
since anakinra, a specific antibody against IL-1β prevents
its effect. The mechanism seems to be independent of
RXR/RAR.75 The same cytokine modulates GST at a
posttranscriptional level.76 In the estrogen-induced
cholestasis model the mechanism of regulation governing
phase II enzymes is as yet unknown.
The down-regulation of Mrp2 occurring in cholestasis
results in the accumulation of different conjugated spe-
cies within the hepatocyte. A portion of these metabolites
is transported to the plasma via multidrug resistance-as-
sociated protein 3 (Mrp3), which is induced during
cholestasis.77 A coordinated decrease in enzyme activities
tends to moderate the accumulation of conjugates. The
disadvantage of the potential increase in non-conjugated
species concentration is counterbalanced by a lesser accu-
mulation of conjugates with toxic effects (e.g. estradiol
17β-glucuronide).64,74
Potential therapeutic approaches based
upon induction of Phase II enzymes and Mrp2
It is well established that certain xenobiotics, including
several of the compounds mentioned earlier, induce the
expression of specific Phase I and II metabolizing en-
zymes. Some of these agents have therapeutic applica-
tions, though usually at lower doses than those demon-
strated to induce metabolizing enzymes in experimental
animals. However, for some specific drugs, induction was
demonstrated in humans. For example SL, administered
as a diuretic to patients with ascitis, increases the depura-
tion of antipyrine, a phenomenon associated with in-
creased activity of specific CYP isoforms.78 As described
earlier, several xenobiotics also induce the expression of
apical transporters, including Mrp2. One of these agents
is rifampicin. It was recently reported that rifampicin in-
duced Mrp2 mRNA and protein levels in human duode-
num.79 Thus, increased elimination of Mrp2 substrates
(eg, drug conjugates of other therapeutic agents) into the
lumen of the gastrointestinal tract during treatment with
rifampicin may represent a new mechanism of drug inter-
actions. Several other studies were specifically focused
on the effect of model inducers on transporter proteins. It
would be of interest to test the potential of such inducers
in counteracting the downregulation of these same pro-
teins occurring in experimental liver diseases (e.g. fol-
lowing estrogen or LPS administration).
An additional therapeutic tool useful for the treatment
of liver disease is the administration of hydrophilic bile
salts such as ursodeoxycholic acid (UDC), or its taurine
derivative, TUDC. Long-term (7-day) feeding of normal
mice with UDC induces the upregulation of canalicular
Mrp2.80 Furthermore, intraperitoneal coadministration of
UDC with the lipophilic, toxic bile salt deoxycholate,
counteracted the down-regulation of the canalicular bile
salt transporter, Bsep.81 Similar protective effects were
observed with UDC on cholic acid-induced decreases in
the expression of basolateral transporters, particularly or-
ganic anion transporters 1 and 4.82
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Conclusion
Metabolic biotransformation of endogenous and exog-
enous compounds renders lipophilic molecules more sol-
uble in water, allowing their excretion in bile, urine or fe-
ces. It is likely that under specific circumstances,
biotransformation systems and membrane transporters
may act in cooperation to increase liver and intestinal
first-pass metabolism and prevent toxicity of endogenous
compounds or xenobiotics incorporated into the body.
Altered rates of metabolism can affect their systemic
availability and residence time, and hence its toxicity or
therapeutic effect. In the case of therapeutic agents, this
can result in a number of undesirable drug-drug interac-
tions. The better understanding of simultaneous regula-
tion of metabolism and transport systems may help to
prevent these undesirable effects.
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